Cargando…

Uncovering the pharmacology of Ginkgo biloba folium in the cell-type-specific targets of Parkinson’s disease

Parkinson’s disease (PD) is the second most common neurodegenerative disease with a fast-growing prevalence. Developing disease-modifying therapies for PD remains an enormous challenge. Current drug treatment will lose efficacy and bring about severe side effects as the disease progresses. Extracts...

Descripción completa

Detalles Bibliográficos
Autores principales: Yan, Yu-Chen, Xu, Zhi-Heng, Wang, Jian, Yu, Wen-Bo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9556873/
https://www.ncbi.nlm.nih.gov/pubmed/36249800
http://dx.doi.org/10.3389/fphar.2022.1007556
_version_ 1784807172116316160
author Yan, Yu-Chen
Xu, Zhi-Heng
Wang, Jian
Yu, Wen-Bo
author_facet Yan, Yu-Chen
Xu, Zhi-Heng
Wang, Jian
Yu, Wen-Bo
author_sort Yan, Yu-Chen
collection PubMed
description Parkinson’s disease (PD) is the second most common neurodegenerative disease with a fast-growing prevalence. Developing disease-modifying therapies for PD remains an enormous challenge. Current drug treatment will lose efficacy and bring about severe side effects as the disease progresses. Extracts from Ginkgo biloba folium (GBE) have been shown neuroprotective in PD models. However, the complex GBE extracts intertwingled with complicated PD targets hinder further drug development. In this study, we have pioneered using single-nuclei RNA sequencing data in network pharmacology analysis. Furthermore, high-throughput screening for potent drug-target interaction (DTI) was conducted with a deep learning algorithm, DeepPurpose. The strongest DTIs between ginkgolides and MAPK14 were further validated by molecular docking. This work should help advance the network pharmacology analysis procedure to tackle the limitation of conventional research. Meanwhile, these results should contribute to a better understanding of the complicated mechanisms of GBE in treating PD and lay the theoretical ground for future drug development in PD.
format Online
Article
Text
id pubmed-9556873
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-95568732022-10-14 Uncovering the pharmacology of Ginkgo biloba folium in the cell-type-specific targets of Parkinson’s disease Yan, Yu-Chen Xu, Zhi-Heng Wang, Jian Yu, Wen-Bo Front Pharmacol Pharmacology Parkinson’s disease (PD) is the second most common neurodegenerative disease with a fast-growing prevalence. Developing disease-modifying therapies for PD remains an enormous challenge. Current drug treatment will lose efficacy and bring about severe side effects as the disease progresses. Extracts from Ginkgo biloba folium (GBE) have been shown neuroprotective in PD models. However, the complex GBE extracts intertwingled with complicated PD targets hinder further drug development. In this study, we have pioneered using single-nuclei RNA sequencing data in network pharmacology analysis. Furthermore, high-throughput screening for potent drug-target interaction (DTI) was conducted with a deep learning algorithm, DeepPurpose. The strongest DTIs between ginkgolides and MAPK14 were further validated by molecular docking. This work should help advance the network pharmacology analysis procedure to tackle the limitation of conventional research. Meanwhile, these results should contribute to a better understanding of the complicated mechanisms of GBE in treating PD and lay the theoretical ground for future drug development in PD. Frontiers Media S.A. 2022-09-29 /pmc/articles/PMC9556873/ /pubmed/36249800 http://dx.doi.org/10.3389/fphar.2022.1007556 Text en Copyright © 2022 Yan, Xu, Wang and Yu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Yan, Yu-Chen
Xu, Zhi-Heng
Wang, Jian
Yu, Wen-Bo
Uncovering the pharmacology of Ginkgo biloba folium in the cell-type-specific targets of Parkinson’s disease
title Uncovering the pharmacology of Ginkgo biloba folium in the cell-type-specific targets of Parkinson’s disease
title_full Uncovering the pharmacology of Ginkgo biloba folium in the cell-type-specific targets of Parkinson’s disease
title_fullStr Uncovering the pharmacology of Ginkgo biloba folium in the cell-type-specific targets of Parkinson’s disease
title_full_unstemmed Uncovering the pharmacology of Ginkgo biloba folium in the cell-type-specific targets of Parkinson’s disease
title_short Uncovering the pharmacology of Ginkgo biloba folium in the cell-type-specific targets of Parkinson’s disease
title_sort uncovering the pharmacology of ginkgo biloba folium in the cell-type-specific targets of parkinson’s disease
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9556873/
https://www.ncbi.nlm.nih.gov/pubmed/36249800
http://dx.doi.org/10.3389/fphar.2022.1007556
work_keys_str_mv AT yanyuchen uncoveringthepharmacologyofginkgobilobafoliuminthecelltypespecifictargetsofparkinsonsdisease
AT xuzhiheng uncoveringthepharmacologyofginkgobilobafoliuminthecelltypespecifictargetsofparkinsonsdisease
AT wangjian uncoveringthepharmacologyofginkgobilobafoliuminthecelltypespecifictargetsofparkinsonsdisease
AT yuwenbo uncoveringthepharmacologyofginkgobilobafoliuminthecelltypespecifictargetsofparkinsonsdisease